Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in Radiographic Axial Spondyloarthritis
NCT07133633Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of tulisokibart in ankylosing spondylitis (AS) (4 arms), sponsored by Merck & Co. Primary endpoint: Assessment of Spondyloarthritis International Society 40 Response at 16 weeks. Started Sep 2025; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07133633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133633.